Mar 15, 2020
Dr. Curtiland Deville is an Associate Professor in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins University School of Medicine. He serves as Clinical Director and Chair of Sibley Radiation Oncology and the Associate Director of the Johns Hopkins National Proton Therapy Center.
He is a graduate of Brown University’s combined undergraduate and graduate Program in Liberal Medical Education (PLME) and a past Doris Duke Clinical Research Fellow at the Yale Cancer Center. He completed his transitional year internship in internal medicine at Harbor Hospital Center in Baltimore, Maryland, and residency in radiation oncology at the Hospital of the University of Pennsylvania, where he joined the junior faculty as an Assistant Professor and served as clinical Chief of the Genitourinary (GU) and Sarcoma Services in the Department of Radiation Oncology and Roberts Proton Therapy Center.
Dr. Deville’s clinical expertise is in treating patients with soft tissue sarcoma and GU malignancies. His research interests include improving tumor targeting and assessing the toxicity profiles using modern radiation techniques such as proton and photon therapy. He has evaluated the implementation of proton therapy for novel indications such as post-prostatectomy therapy, pencil beam scanning, and plan robustness evaluations. He has co-authored over 80 peer-reviewed publications, including the first paper ever on the clinical use of post-prostatectomy proton therapy and textbook chapters on the use of proton therapy for soft tissue sarcoma and prostate cancer. He is on the research investigative team for the largest national trial comparing proton and photon therapy (COMPPARE), and serves as a Senior GU editor for the journal, Advances in Radiation Oncology.
Dr. Deville also has a research interest in physician workforce diversity in specialties that are disproportionately underrepresented by women and minorities. He serves as the Immediate Past Chair of the American Society for Radiation Oncology’s (ASTRO) Committee on Health Equity, Diversity and Inclusion, and as the Chair of the American Society for Clinical Oncology’s (ASCO) Diversity in Oncology Subcommittee.